Table 3.
Characteristics of 67 patients on bevacizumab-based therapy by BMI
| BMI (kg/m2) | Normal (BMI 18.5–25) | Overweight (BMI 25–29.9) | Obese (BMI ≥30) |
|---|---|---|---|
|
| |||
| Number of patients (n=67) | 31* | 17 | 19 |
|
| |||
| BMI (kg/m2) | |||
|
| |||
| Median (range) | 22.5 (18.5–24.6) | 27.4 (25–29.7) | 32.4 (30.7–41.5) |
|
| |||
| Age, years | |||
| Median (range) | 59 (27–77) | 62 (42–71) | 58 (27–71) |
|
| |||
| Locations of tumor, n | |||
| Liver parenchymal | 14 | 4 | 5 |
| Deep lymph nodes | |||
| Superficial lymph nodes | 5 | 1 | 3 |
| Intra-abd/pelvic mass | 2 | 2 | 3 |
| Abdominal/chest wall | 7 | 6 | 5 |
| Lung (pleural) | 4 | 1 | |
| Other | 2 | 1 | |
| Psoas m 1 | Vaginal mass 1 | ||
|
| |||
| Median diameter of target tumor (cm; range) | 2.8 (1.2–7) | 2.5 (1.3–10) | 2.75 (1–11) |
|
| |||
| Complication | 1 minor basilar pneumothorax | 1 minor vasovagal reaction | 1 minor liver subcapsular hematoma |
*
No patient was under weight range